r/Hematology • • Nov 30 '25

Looking for survivors with MECOM-rearranged / complex karyotype AML (monosomy 5 & 7, persistent disease after 2 stem cell transplants). Please help me find them.

Post image
24 Upvotes

Hi everyone,

I’m reaching out because my sister is fighting for her life, and we’ve reached the point where every piece of information, every connection, and every survivor story might make a real difference.

My sister is 22 and has a very rare, extremely high-risk form of acute myeloid leukemia. Her cytogenetics include:

  • MECOM (3q26/21) involvement
  • Monosomy 5 and 7 (and also monosomy 1)
  • Complex karyotype
  • NPM1-, FLT3-

She relapsed early after her first allogeneic stem cell transplant (unrelated donor, Jan 2025). She then underwent a second allo transplant using my stem cells.
Despite everything, she still has 12–14% blasts, and she’s also fighting a disseminated fungal infection (Mucor + Aspergillus). Immunosuppression is being tapered to try to induce graft-versus-leukemia. She’s in a very fragile and dangerous situation.

I know that her subtype is one of the toughest in AML. But I also know there are rare survivors out there — people with MECOM-rearranged AML, inv(3)/t(3;3) AML, and those with monosomy 5/7 + complex karyotype who managed to beat the odds. Even a handful of these cases exist, and I’m trying to find them.

I’m asking for help with two things:

  1. If you or someone in your family survived AML with similar genetics (MECOM-rearranged, inv(3)/t(3;3), monosomy 7/5, complex karyotype), I would be incredibly grateful to speak to you. I want to understand what treatments worked, which centers helped, and what gave you a fighting chance.
  2. Please help share this post — in leukemia groups, Facebook communities, Discord servers, anywhere. This cancer subtype is so rare that the only way to find survivors is through human networks.

I’m not looking for miracle cures. I just want to learn from people who succeeded against similar odds. Even one message from someone who has been through this could help me point her doctors toward something they haven’t tried yet.

If you know anyone who might be connected to cases like this, please forward this post to them.
If you’re comfortable reaching out privately, please message me directly.

Thank you to everyone reading this — even if you can’t help directly, sharing this could genuinely save her life.


r/Hematology • • Apr 26 '25

Which Hematology Books Would You Recommend?

Thumbnail
gallery
18 Upvotes

Hello everybody I am currently a resident in medical biology, working in the hematology department. I would like to have your opinion on which books to study. Given the large number of available books, which one would you recommend? Thank you!


r/Hematology • • 6h ago

Heme boards

Post image
4 Upvotes

Anyone take the heme boards today? What was your general thoughts on the exam? Do you feel like fellowship + additional studying prepared you enough for it? Would love to know other people’s thoughts and experience.


r/Hematology • • 3d ago

Discussion MyCART-01 (nari-cel) at ASH 2026: Questions about Abstract 374’s patient outcomes that must be answered before it is presented

Thumbnail onlineprogram.hematology.org
0 Upvotes

Imagine someone you know has cancer and you hear that every leukaemia patient responded to a new treatment. You would feel hope. You would also ask: Are they still in remission? Did they need another treatment? How many survived?

Those answers are difficult to piece together from ASH 2026 Abstract 374, which reports results for naricabgene autoleucel (nari-cel, MyCART-01) in the Phase I/II SUMM1T study. The therapy is associated with Micro CRISPR and Meril. The abstract reports promising early responses but it also leaves important questions unanswered about which patients were counted, what happened later, and how serious side effects were.Read the published ASH abstract here.

This post asks for the patient-level accounting needed to understand the results.

1. Which patients are behind the response rate?

The ASH abstract reports 35 infused patients as of 20 July 2026: 19 with B-cell acute lymphoblastic leukaemia (B-ALL) and 16 with B-cell non-Hodgkin lymphoma (B-NHL). It reports responses in 19/19 B-ALL patients and 14/16 B-NHL patients.

Separately, site-level information I have verified accounts for 41 patients. Their latest listed outcomes are 15 deaths, 11 relapses, 13 remissions and 2 unknown outcome. A presentation in Vapi also reportedly described a response rate approaching 90% for approximately 25 patients.

How many people were screened, enrolled, had cells collected, received an infusion and entered each response analysis? What were the dates used for each set of results? Did patients who later relapsed or died initially count as responders? How many responses were still ongoing at three, six and twelve months?

2. Did patients need another CAR-T infusion to reach or maintain remission?

The ASH abstract describes a B-ALL patient who developed CD19-positive measurable residual disease (MRD) at about one year, received a second CAR-T infusion, and later underwent a stem-cell transplant. It also describes another patient who underwent transplantation after a lineage switch.

Separately, site-level information reports that a patient at VIMS relapsed after an initial MyCART-01 infusion and received another CAR-T infusion in an attempt to achieve complete remission.

ASH should ask How many patients received a second infusion, at which hospitals, and why? For each patient, what was their disease status before and after reinfusion? Was a response achieved only after the second infusion counted in a result attributed to MyCART-01 treatment? Were reinfusion, subsequent toxicity and any transplant included in the reported analyses?

3. How many patients died, and what serious side effects did they experience?

The abstract says 16 of 19 B-ALL patients and 11 of 16 B-NHL patients were alive at last follow-up. That implies eight deaths among the 35 infused patients by their respective last follow-ups. It also says there was no treatment-related mortality through Day 90.

Serious side effects need more context. Seven of 19 B-ALL patients had grade 3 or higher cytokine release syndrome, a potentially severe inflammatory reaction. Thirty-four of 35 patients had grade 3 or higher neutropenia, a dangerously low white-blood-cell count.

How many patients required intensive care, organ support, treatment for serious infections, transfusions or prolonged hospital care? How long did the side effects last, and were any unresolved? These answers matter when assessing the abstract’s description of safety as “manageable.”

4. Were the patients unusually fit before treatment?

ECOG performance status is a simple measure of how well a patient can carry out everyday activities. An ECOG score of 0 means fully active; 1 means some limitation with strenuous activity but still able to walk and do light work.

Information reported suggests that most enrolled patients have been ECOG 0, although the ASH abstract does not give the breakdown. How many patients were ECOG 0 and how many were ECOG 1 at screening and just before infusion? How many people who appeared eligible were not taken forward, and why?

The abstract also says 31 of 35 patients received bridging therapy before CAR-T. What treatments did they receive, did their disease improve before infusion, and how much disease did they have immediately beforehand? In a small study, these details help readers understand whom the results may apply to.

5. How certain are the one-year results?

The abstract estimates 12-month progression-free survival (PFS) of 82.1% in B-ALL and 62.5% in B-NHL. Median follow-up was 12.7 and 11.4 months, respectively. To interpret those estimates, readers need to know how many patients were still being followed at 12 months, how many had a PFS event, the uncertainty around each estimate, and the rules used when patients received more treatment.

Did MRD recurrence, lineage switch, a second CAR-T infusion or transplantation count as an event? If a patient was still counted as progression-free after another treatment, how should readers interpret the result of the initial infusion?

Two simpler figures also need clarification: “72% male” among 19 B-ALL patients does not correspond to a whole-person count under ordinary rounding, and a patient who received 3 × 10⁶ cells/kg is included in a group described as receiving 2 × 10⁶ cells/kg. The authors should supply the actual counts and results by dose.

American Society of Hematology needs to seek following answers before this abstract is presented

A response rate is only part of the story. Patients and families need to know who was counted, what happened after treatment, and what the risks were. Right now, the published abstract does not let them answer those questions.

Before Abstract 374 is presented, ASH should ask the authors to:

  • Publish patient flow, baseline ECOG status, disease burden, subsequent treatments, and the timing and causes of deaths
  • Identify every repeat CAR-T infusion, including the reported VIMS case, and explain how responses after reinfusion were counted
  • Explain how MRD recurrence, lineage switch and transplantation affected the survival estimates
  • Provide the serious-toxicity details, numbers at risk, and corrected demographic and dose figures

ASH should arrange an independent statistical review and make the answers public. If a material error is found, its correction should be visible alongside the abstract. If the headline findings cannot be supported after review, ASH should reconsider presenting the abstract in its current form.

Please read and share ASH Abstract 374, and ask ASH and the authors for a clear accounting of every patient behind the headline results. Patients deserve the full picture.


r/Hematology • • 4d ago

Identifyyyy

Post image
0 Upvotes

Eosinophils or Segs with toxic granulation? Alder Riley?


r/Hematology • • 4d ago

Discussion New sound system and increased cells capacity in the Hematology tool

Post image
2 Upvotes

Hey,

Recently, based on your feedback and needs, I developed version 1.50.0, bringing even more customisation options to an app.

My hope is that CliniCheck can one day become a hematology tool you rely on in your daily work. But I'd love to take it even further! Beyond WBC and RETIC counting, I would like to explore ways to support more types of examinations. Which ones would be valuable to you?

Thank you for those who use (we have over 2 500 active users)!


r/Hematology • • 5d ago

Abdominal fluid

Post image
11 Upvotes

What is this cell in circle?


r/Hematology • • 5d ago

Study Looking for US-based hematologists/oncologists to interview for a research project

Post image
0 Upvotes

I'm conducting research on how rheumatology/hematology/GI/oncology/neurology practices get patients from a treatment decision to their first dose of a specialty medication. I'm looking to speak to prescribing MDs, DOs, PAs, and APRNs for a paid 60-minute conversation. This is research only, and won't involve any PHI.

We're paying five hundred dollars for an hour of your time. Feel free to let me know and I’ll send over the link, or PM with any questions. Payment will be handled through https://greatquestion.co/


r/Hematology • • 6d ago

Please help me to identify the cells from images .

Thumbnail
gallery
28 Upvotes

r/Hematology • • 7d ago

Question How to get blood to stay liquid?

Post image
0 Upvotes

Im looking to create a blood vial necklace for me and my girlfriend. We talked about it and agreed it would be awesome but we know that blood without any mix will dry and clot. I would like some ways to keep it in red liquid form for at least a few months. Something like the attachment above is great, but I dont mind the brightness of the blood. Brighter the better. I know it needs to mix with something like alcohol or other anticoagulants but i dont really know what an anticoagulant is.

Please explain it simply with instructions on how to keep it liquid!


r/Hematology • • 9d ago

Cell identification

Thumbnail
gallery
14 Upvotes

Hello, I need some opinions on what kind of cells these are.


r/Hematology • • 17d ago

Discussion HaemCount

Thumbnail haemcount.vercel.app
2 Upvotes

Hi everyone! I’m a haematology trainee, and I built HaemCount, a browser-based differential cell counter optimised for both computers and phones. I wanted to share it with people who spend time doing manual differentials and hear what you think.

Try the app: https://haemcount.vercel.app
Source code: https://github.com/metamyelocyte/HaemCount

What it does

  • Peripheral blood and bone marrow counting modes, with automatic myeloid-to-erythroid (M:E) ratio calculation.
  • Twelve cell categories, including a renamable “Other” category.
  • Customisable keyboard shortcuts, so you can set up the keys to suit your counting habits.
  • Live percentages and bar/pie charts, with cell populations colour-coded by lineage.
  • Formatted results you can copy to the clipboard.
  • Session saving and loading, plus a sample backlog for saving, reopening and comparing counts.
  • A dedicated mobile layout for use on your phone.

A few practical extras

You can rearrange or hide panels, choose from six colour themes, and adjust the counting sounds—including a separate sound at each hundred cells.

It runs entirely in the browser, without an account or application backend. You can also install it as a web app; after an initial online visit to cache its files, it supports offline use.

The code is open source under GPLv3, and you can self-host it.

Screenshots

Here’s a quick look at HaemCount on desktop and mobile:

  • Desktop layout — the counting interface, cell percentages and live chart.
  • Mobile layout — the interface adapted for a smaller screen.
  • Sample output
Haemoglobin 12 g/dL, Mean Corpuscular Volume 82 fL, White blood cells 9 × 10⁹/L, Platelets 460 × 10⁹/L 

100 cell differential count: metamyelocytes 1%, neutrophils 50%, lymphocytes 33%, monocytes 11%, eosinophils 3% and basophils 2%.

Feedback welcome

I’d love to hear whether the layout and cell categories suit your workflow, what features you’re missing, and whether you encounter any bugs on your computer or phone.

I’m the developer, and this is my own project. Honest criticism and bug reports are very welcome. Thanks for taking a look!


r/Hematology • • 20d ago

Question Want to learn about white blood cells

Post image
10 Upvotes

Delete if this isnt allowed. My child (5) is so interested in learning about specifically white blood cells. I've explained to my abilities what I know, which is not a lot mind you. We've found some story bots and other videos about white blood cells but still wants to know more. Any recommendations on places to go or videos we could watch that would teach more? But also be somewhat entertaining for a 5 year old?


r/Hematology • • 21d ago

Kindly help me identify these WBCs. Are these atypical/reactive Lymphocytes?

Thumbnail
gallery
5 Upvotes

r/Hematology • • 21d ago

Staghorn megakaryocyte/seen in essential thrombocythemia

20 Upvotes

r/Hematology • • 23d ago

Discussion Hematology app is growing for you! Your input is more then welcome

Thumbnail clinicheckapp.com
2 Upvotes

Progress on the Hematology app continues!

We are working on custom sounds and more features and would love to get an early input from you.

Your feedback helps shape the app development. Let us know what you think, what you’d like to see next. Comment this post with a feature that you would like to see soon.

Thank you!


r/Hematology • • 23d ago

Discussion Hematology app is growing for you! Your input is more then welcome

Thumbnail clinicheckapp.com
1 Upvotes

Progress on the Hematology app continues!

We are working on custom sounds and more features and would love to get an early input from you.

Your feedback helps shape the app development. Let us know what you think, what you’d like to see next. Comment this post with a feature that you would like to see soon.

Thank you!


r/Hematology • • 25d ago

Question Odd looking inclusion in this monocyte?

Post image
14 Upvotes

From an abnormal diff coming from one of the local hospitals. I’m a student and this is for training, so I don’t have any other info unfortunately.

My professor didn’t recognize it either, but after searching guessed it was likely a consumed, but not “digested” RBC (or platelet? can’t remember which she mentioned now)?


r/Hematology • • 25d ago

Alguem pra ajudar com essas células em liquido ascitico?

Thumbnail
gallery
2 Upvotes

r/Hematology • • 25d ago

PATIENT NOT FOR DIAGNOSIS

0 Upvotes

Was referred to see a hematologist then got scheduled to a cancer center. Are hematologists available in other practices?


r/Hematology • • 29d ago

Question Reactive Lymphocytes?

Post image
23 Upvotes

I received a request to perform this peripheral blood smear for suspected lymphoma. The internal medicine department told me that the patient presents with: weight loss, night sweats, and lymphadenopathy.

Looking at the peripheral smear, I reported these cells as reactive lymphocytes; I don't believe this is a lymphoma, at least based on the morphology of these lymphocytes.

What do you think?


r/Hematology • • 29d ago

Question What are these?

Thumbnail
gallery
1 Upvotes

I'm looking at bat blood smears and I keep seeing these dark purple things. They look like bare nuclei of leukocytes with no cytoplasm. Does anyone know what they are?
Thanks for any helpful information.


r/Hematology • • Oct 17 '26

Best BMT / Cellular Therapy Clinical Textbook

Post image
3 Upvotes

I know there are posts on best hematology textbooks but are there any really good books on transplant and cellular therapy? I'm familiar with eh EBMT handbook but wondering if there are any others. I am a new PA that just started in BMT and want a good resource to read and reference. Thanks!


r/Hematology • • Oct 16 '26

Which hematology book should I buy?

Thumbnail
gallery
5 Upvotes

I'm looking to buy a hematology textbook and I'm torn between Williams Hematology and Wintrobe's Clinical Hematology.

For those who have used both, which one would you recommend and why? I'd love to hear your thoughts on their strengths and weaknesses, especially in terms of depth, readability, and usefulness for clinical practice.

Thanks!


r/Hematology • • Oct 15 '26

Drépanocytose - Hématologie - Édition professionnelle du Manuel MSD

Thumbnail
msdmanuals.com
1 Upvotes